A phase I study for Methylmalonic acidemia (MMA)
Latest Information Update: 28 Sep 2020
At a glance
- Drugs AAV based gene therapies Asklepios BioPharmaceutical/Selecta Biosciences (Primary)
- Indications Methylmalonic acidaemia
- Focus Adverse reactions
- Sponsors Selecta Biosciences
- 28 Sep 2020 New trial record
- 06 Aug 2020 According to a Selecta Biosciences media release, this trial is conducted in collaboration with AskBio, is expected to enter the clinic in the first half of 2021, with preliminary data expected in 2H 2021.